Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	131.55	141.79	118.32
Short-Term Investments	598.64	378.86	277.14
Cash & Short-Term Investments	730.19	520.65	395.46
Cash Growth	40.24%	31.66%	-
Other Current Assets	11.17	9.06	2.95
Total Current Assets	741.36	529.71	398.41
Net Property, Plant & Equipment	14.38	13.32	2.59
Long-Term Investments	172.73	210.42	-
Other Long-Term Assets	8.67	0.5	0.4
Total Assets	937.13	753.95	401.4
Accounts Payable	1.22	1.07	2.14
Accrued Expenses	23.18	24.26	17.31
Current Portion of Leases	3.5	3.23	1.1
Total Current Liabilities	27.91	28.56	20.56
Long-Term Leases	5.35	8.6	0.93
Total Long-Term Liabilities	5.35	8.6	0.93
Total Liabilities	33.25	37.16	21.49
Common Stock	0	0	-
Additional Paid-in Capital	1,465	1,022	503.35
Accumulated Other Comprehensive Income	1.08	0.92	0.33
Retained Earnings	-561.76	-305.92	-123.77
Shareholders' Equity	903.88	716.79	379.91
Total Liabilities & Equity	937.13	753.95	401.4
Total Debt	8.85	11.83	2.03
Net Cash (Debt)	721.34	508.82	393.43
Net Cash Growth	41.77%	29.33%	-
Net Cash Per Share	11.89	9.22	15.73
Book Value	903.88	716.79	379.91
Book Value Per Share	14.89	12.99	15.19
Tangible Book Value	903.88	716.79	379.91
Tangible Book Value Per Share	14.89	12.99	15.19

Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q